1
|
Martineau S, Cristea IA, Chevance A, Fanelli D, Naudet F. Are large prospective trials on antidepressants in mental disorders seeding trials? A descriptive study of trials registered on ClinicalTrials.gov. BMJ Open 2023; 13:e062913. [PMID: 37558440 PMCID: PMC10414101 DOI: 10.1136/bmjopen-2022-062913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Accepted: 07/25/2023] [Indexed: 08/11/2023] Open
Abstract
OBJECTIVES This descriptive study of registered trials aimed to identify large clinical trials on antidepressants for mental disorders: (1) to assess what proportion could be labelled as 'seeding trials' (trials for marketing purposes) and (2) to describe their methodological characteristics and outcomes. DESIGN A search was conducted across all trials registered on ClinicalTrials.gov by drug name in March 2017. SETTING All trials registered in the database of ClinicalTrials.gov were screened. Large registered studies were received and studies focusing prospectively on the effects of antidepressants in mental health disorders. Specific data items were extracted automatically, and subsequently inspected, corrected and completed by hand. PARTICIPANTS Prospective studies were selected focusing on the effects of antidepressants in any mental health disorder with 800 participants or more planned for inclusion. MAIN OUTCOME MEASURES Three members from the study team independently assessed the following 'seeding trial' characteristics in each registered study: a high level of involvement of the product manufacturer in the study design, in the data analysis and reporting of the study, an abnormally low ratio of patient numbers to study site, spin and/or omissions of clinically relevant findings in the abstracts, and conclusions that focused on secondary endpoints and surrogate markers. Secondary outcomes were the exploration of a functional outcome and suicidality. RESULTS 31 trials were identified from clinical trials database. 18/31 were published (58%). 8 of these 18 (44%) studies were identified as possible seeding trials. 13/31 (42%) large trials planned to explore functioning and 5/31 (16%) suicidality. CONCLUSIONS Large trials are rare in the field of antidepressant research. Some could be 'seeding trials'. Few explored suicidality. Identifying seeding trials from incomplete data entries in registries, especially when almost half of the studies were still unpublished, posed considerable challenges. The delay between our research and publication limits the strength of our conclusions. PROSPERO REGISTRATION NUMBER CRD42017065591.
Collapse
Affiliation(s)
- Samuel Martineau
- University of Rennes, CHU Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, CIC 1414 (Centre of Clinical Investigation of Rennes), Rennes, France
| | - Ioana-Alina Cristea
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Astrid Chevance
- Inserm U1153 Team METHODS, University Paris Descartes, Service Hospitalo-Universitaire de Psychiatrie, Centre Hospitalier Sainte-Anne, Paris, France
| | - Daniele Fanelli
- Department of Methodology, London School of Economics and Political Science, London, UK
| | - Florian Naudet
- University of Rennes, CHU Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, CIC 1414 (Centre of Clinical Investigation of Rennes), Rennes, France
- Institut Universitaire de France (IUF), Paris, France
| |
Collapse
|
2
|
Matheson A. The "Monsanto papers" and the nature of ghostwriting and related practices in contemporary peer review scientific literature. Account Res 2023:1-30. [PMID: 37424374 DOI: 10.1080/08989621.2023.2234819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 07/06/2023] [Indexed: 07/11/2023]
Abstract
The Monsanto company - now acquired by Bayer - has been accused of ghostwriting articles within peer review literature, with the goal of using influential names to front its content in defence of the herbicide Roundup. Here, I conduct a detailed analysis of three Monsanto review articles and a five-article journal supplement for which detailed information from company emails is publicly available following litigation over Roundup. All the articles had external, but not Monsanto authors, and ghostly practices including ghost authorship, corporate ghost authorship and ghost management were evident in their development. There was clear evidence of ghostwriting - that is, drafting of the manuscript by non-authors - in only two cases. I found no evidence of undeserving authorship among the external authors. The articles complied with the disclosure requirements of their journals, save for the journal supplement. While crude ghostwriting did occur, much of the literature involved subtler practices through which Monsanto exercised control over content, while the attribution of the articles downplayed the company's role - and correspondingly aggrandized that of the external authors. Such practices are widespread within industry journal literature and are the responsibility of byline authors and journals as well as corporations. I discuss these cultural problems and consider remedies.
Collapse
|
3
|
Hunt LM, Arndt EA, Bell HS, Howard HA. Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs. JOURNAL OF BIOETHICAL INQUIRY 2021; 18:477-497. [PMID: 34487285 PMCID: PMC8568684 DOI: 10.1007/s11673-021-10119-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 04/24/2021] [Indexed: 05/15/2023]
Abstract
While pharmaceutical industry involvement in producing, interpreting, and regulating medical knowledge and practice is widely accepted and believed to promote medical innovation, industry-favouring biases may result in prioritizing corporate profit above public health. Using diabetes as our example, we review successive changes over forty years in screening, diagnosis, and treatment guidelines for type 2 diabetes and prediabetes, which have dramatically expanded the population prescribed diabetes drugs, generating a billion-dollar market. We argue that these guideline recommendations have emerged under pervasive industry influence and persisted, despite weak evidence for their health benefits and indications of serious adverse effects associated with many of the drugs they recommend. We consider pharmaceutical industry conflicts of interest in some of the research and publications supporting these revisions, and in related standard-setting committees and oversight panels. We raise concern over the long-term impact of these multifaceted involvements. Rather than accept industry conflicts of interest as normal, needing only to be monitored and managed, we suggest challenging that normalcy, and ask: what are the real costs of tolerating such industry participation? We urge the development of a broader focus to fully understand and curtail the systemic nature of industry's influence over medical knowledge and practice.
Collapse
Affiliation(s)
- Linda M Hunt
- Department of Anthropology, Michigan State University, 655 Auditorium Drive, East Lansing, MI, 48824, USA.
| | - Elisabeth A Arndt
- Department of Anthropology, Michigan State University, 655 Auditorium Drive, East Lansing, MI, 48824, USA
- College of Osteopathic Medicine, Michigan State University, 909 Wilson Road West Fee Hall, Room 317, East Lansing, MI, 48824, USA
| | - Hannah S Bell
- Department of Anthropology, Michigan State University, 655 Auditorium Drive, East Lansing, MI, 48824, USA
| | - Heather A Howard
- Department of Anthropology, Michigan State University, 655 Auditorium Drive, East Lansing, MI, 48824, USA
- University of Toronto, Centre for Indigenous Studies, 563 Spadina Avenue, Toronto, ON, M5S 2J7, Canada
| |
Collapse
|
4
|
Yarborough M. Do we really know how many clinical trials are conducted ethically? Why research ethics committee review practices need to be strengthened and initial steps we could take to strengthen them. JOURNAL OF MEDICAL ETHICS 2021; 47:572-579. [PMID: 32532827 PMCID: PMC8011810 DOI: 10.1136/medethics-2019-106014] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Revised: 05/19/2020] [Accepted: 05/22/2020] [Indexed: 05/08/2023]
Abstract
Research Ethics Committees (RECs) play a critical gatekeeping role in clinical trials. This role is meant to ensure that only those trials that meet certain ethical thresholds proceed through their gate. Two of these thresholds are that the potential benefits of trials are reasonable in relation to risks and that trials are capable of producing a requisite amount of social value. While one ought not expect perfect execution by RECs of their gatekeeping role, one should expect routine success in it. This article reviews a range of evidence showing that substantial numbers of ethically tainted trials are receiving REC approvals. Many of the trials are early phase trials that evidence shows have benefits that may not be reasonable compared with their risks and many others are later trials that evidence shows may lack sufficient social value. The evidence pertains to such matters as methodologically inadequate preclinical studies incapable of supporting the inferences that REC members must make about the prospects for potential benefit needed to offset the risks in early phase trials and sponsorship bias that can cause improperly designed, conducted, analysed and reported later phase trials. The analysis of the evidence makes clear that REC practices need to be strengthened if they are to adequately fulfil their gatekeeping role. The article also explores options that RECs could use in order to improve their gatekeeping function.
Collapse
Affiliation(s)
- Mark Yarborough
- Bioethics Program, University of California Davis, Sacramento, CA 95817, USA
| |
Collapse
|
5
|
Vergara-Merino L, Verdejo C, Franco JVA, Escobar Liquitay C, Urrútia G, Klabunde R, Pérez P, Sánchez L, Madrid E. Registered trials address questions already answered with high-certainty evidence: A sample of current redundant research. J Clin Epidemiol 2021; 134:89-94. [PMID: 33561527 DOI: 10.1016/j.jclinepi.2021.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 12/21/2020] [Accepted: 01/21/2021] [Indexed: 10/22/2022]
Abstract
OBJECTIVE To identify clinical trials registered later than 2015, that study the effect of an intervention on a primary outcome whose "Certainty of Evidence" (CoE) has already been rated "high" in a Cochrane SR. STUDY DESIGN AND SETTING We searched the Cochrane Library for all SRs from 2015. We analyzed SRs of interventions and excluded withdrawn reviews or those with no Summary of Findings (SoF) table. We retrieved the GRADE CoE ratings of each SR's primary outcomes in the SoF tables and identified those rated "high." We searched the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials to identify records of clinical studies that tackled those outcomes and were registered after the date of publication of the respective 2015 SR. RESULTS We selected 602 SRs. Eighty-one contained a "high" CoE rating on at least one primary outcome, totaling 152 primary outcomes rated "high." We found 39 clinical trials registered for primary outcomes with evidence already rated as "high" in a 2015 Cochrane SR. CONCLUSION This study shows the existence of clinical trials registered to study primary outcomes whose CoE has already been rated "high" in a Cochrane SR.
Collapse
Affiliation(s)
- Laura Vergara-Merino
- Cochrane Chile, Associate Centre Universidad de Valparaíso, Angamos 655, room 1111, Viña del Mar, Chile; Interdisciplinary Centre for Health Studies CIESAL, Universidad de Valparaíso, Chile; School of Medicine, Universidad de Valparaíso, Angamos 655, Viña del Mar, Chile
| | - Catalina Verdejo
- Cochrane Chile, Associate Centre Universidad de Valparaíso, Angamos 655, room 1111, Viña del Mar, Chile; School of Medicine, Universidad de Valparaíso, Angamos 655, Viña del Mar, Chile
| | - Juan Victor Ariel Franco
- Centro Cochrane Asociado, Biblioteca Central, Instituto Universitario Hospital Italiano, Potosí 4265, Zip code: C1199 Buenos Aires, Argentina
| | - Camila Escobar Liquitay
- Centro Cochrane Asociado, Biblioteca Central, Instituto Universitario Hospital Italiano, Potosí 4265, Zip code: C1199 Buenos Aires, Argentina
| | - Gerard Urrútia
- Centro Cochrane Iberoamericano, Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau) CIBERESP, Hospital de la Santa Creu i Sant Pau C/ Sant Antoni Maria Claret, 167 Pavelló 18, planta 0 08025 Barcelona, España
| | - Rachel Klabunde
- Cochrane Chile, Associate Centre Universidad de Valparaíso, Angamos 655, room 1111, Viña del Mar, Chile
| | - Paulina Pérez
- Cochrane Chile, Associate Centre Universidad de Valparaíso, Angamos 655, room 1111, Viña del Mar, Chile; School of Medicine, Universidad de Valparaíso, Angamos 655, Viña del Mar, Chile
| | - Luna Sánchez
- School of Medicine, Universidad de Valparaíso, Angamos 655, Viña del Mar, Chile
| | - Eva Madrid
- Cochrane Chile, Associate Centre Universidad de Valparaíso, Angamos 655, room 1111, Viña del Mar, Chile; Interdisciplinary Centre for Health Studies CIESAL, Universidad de Valparaíso, Chile.
| |
Collapse
|
6
|
Relationships among commercial practices and author conflicts of interest in biomedical publishing. PLoS One 2020; 15:e0236166. [PMID: 32706798 PMCID: PMC7380625 DOI: 10.1371/journal.pone.0236166] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2020] [Accepted: 06/30/2020] [Indexed: 11/29/2022] Open
Abstract
Recently, concerns have been raised over the potential impacts of commercial relationships on editorial practices in biomedical publishing. Specifically, it has been suggested that certain commercial relationships may make editors more open to publishing articles with author conflicts of interest (aCOI). Using a data set of 128,781 articles published in 159 journals, we evaluated the relationships among commercial publishing practices and reported author conflicts of interest. The 159 journals were grouped according to commercial biases (reprint services, advertising revenue, and ownership by a large commercial publishing firm). 30.6% (39,440) of articles were published in journals showing no evidence of evaluated commercial publishing relationships. 33.9% (43,630) were published in journals accepting advertising and reprint fees; 31.7% (40,887) in journals owned by large publishing firms; 1.2% (1,589) in journals accepting reprint fees only; and 2.5% (3,235) in journals accepting only advertising fees. Journals with commercial relationships were more likely to publish articles with aCOI (9.2% (92/1000) vs. 6.4% (64/1000), p = 0.024). In the multivariate analysis, only a journal’s acceptance of reprint fees served as a significant predictor (OR = 2.81 at 95% CI, 1.5 to 8.6). Shared control estimation was used to evaluate the relationships between commercial publishing practices and aCOI frequency in total and by type. BCa-corrected mean difference effect sizes ranged from -1.0 to 6.1, and confirm findings indicating that accepting reprint fees may constitute the most significant commercial bias. The findings indicate that concerns over the influence of industry advertising in medical journals may be overstated, and that accepting fees for reprints may constitute the largest risk of bias for editorial decision-making.
Collapse
|
7
|
Yarborough M. Rescuing Informed Consent: How the new "Key Information" and "Reasonable Person" Provisions in the Revised U.S. Common Rule open the door to long Overdue Informed Consent Disclosure Improvements and why we need to walk Through that door. SCIENCE AND ENGINEERING ETHICS 2020; 26:1423-1443. [PMID: 31872365 PMCID: PMC7286844 DOI: 10.1007/s11948-019-00170-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 12/16/2019] [Indexed: 05/11/2023]
Abstract
There is substantial published evidence showing that countless people enroll each year in ethically deficient clinical trials. Many of the trials are problematic because the quality of the science used to justify their launch may not be sufficiently vetted while many other trials may lack requisite social value. This poses the question: why do people volunteer for them? The answer resides in large part in the fact that informed consent practices have historically masked, rather than disclosed, the information that would alert research candidates to the ethically problematic nature of the trials. The "reasonable person" and "key information" provisions in the revised US Common Rule create the opportunity to correct this historical shortcoming. Two sources are employed to shed light on what the "key information" is that should be disclosed to a "reasonable person": the original disclosure aims of the Nuremberg Code, as well as an extensive body of meta-research evidence. Those sources jointly support a range of new disclosures in the informed consent process that would unmask the heretofore undisclosed information. The resulting proposed new disclosures pertain to the overall success prospects of clinical trials, the quality of the prior research that both forms the basis of clinical trials and informs assessment of their risks and benefits, the potential social value of clinical trials, and the commercial purposes of clinical trials.
Collapse
Affiliation(s)
- Mark Yarborough
- Bioethics Program, University of California Davis Health, 4150 V Street, Suite G100, Sacramento, CA, 95817, USA.
| |
Collapse
|
8
|
Laking G. Pre-marketing is a type of marketing. Intern Med J 2019; 49:1067-1069. [PMID: 31507041 DOI: 10.1111/imj.14431] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Revised: 07/04/2019] [Accepted: 07/04/2019] [Indexed: 11/28/2022]
Affiliation(s)
- George Laking
- Northland District Health Board, Jim Carney Cancer Centre, Whangārei, New Zealand
| |
Collapse
|
9
|
Matheson A. Can self-regulation deliver an ethical commercial literature? A critical reading of the "Good Publication Practice" (GPP3) guidelines for industry-financed medical journal articles. Account Res 2019; 26:85-107. [PMID: 30607994 DOI: 10.1080/08989621.2018.1564663] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Much medical journal literature is developed by the pharmaceutical and device industries, sometimes with assistance from marketing agencies, writers, and academics. This literature is vulnerable to commercial bias. The publications trade issues self-regulatory ethical guidelines for its production, called "Good Publication Practice" (GPP). I evaluated the most recent iteration, GPP3. The most progressive recommendations in GPP3 call for complete publication of all clinical trials, and full data sharing. GPP3 makes numerous further recommendations more directly concerning the publications trade. Many of these repeat existing editorial requirements, chiefly those of the International Committee of Medical Journal Editors, but readers are not adequately advised of this. Despite its emphasis on ethical and transparent reporting, the detail of GPP3 enables continued use of academic medical literature for drug marketing, on the basis of commercial steerage of content, coupled with the attribution of published articles to collaborating academic authors. As such, GPP3 provides a de facto manual for how marketing through academic journal content can be conducted in compliance with contemporary editorial standards. Consequently, the self-regulatory GPP3 guidelines are not a sound basis for the production of unbiased industry-financed medical journal literature. I suggest improvements for future iterations of these influential guidelines.
Collapse
|